IMAB News and Press, I-MAB From 03/29/24

China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...

2024-03-18 10:15:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for IMAB on March 18, 2024 07:52AM ET. The previous analyst recommendation was Overweight. IMAB was trading at $1.75 at issue of the analyst recommendation. The overall analyst consensus : BUY....

2024-03-14 17:11:38 ET More on I-Mab Biopharma I-Mab: Trading Below Net Cash With Multiple Upside Options I-Mab to divest Chinese assets amid rising geopolitical tensions Read the full article on Seeking Alpha For further details see: I-Mab Biopharma GAAP...

I-Mab Reports Full Year 2023 Financial Results and Business Update PR Newswire Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 ...

2024-02-18 03:28:21 ET Summary I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over $400 million in cash, and the potential to receive...

2024-02-11 01:25:00 ET Summary I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 M. Anbogen Therapeutics raised $12.5M in a Series A funding round. to advance its two lead drug candidates. Bayer signed a non-binding Letter of Intent to m...

2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...

I-Mab Signs Agreement to Divest its Assets and Business Operations in China PR Newswire Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech Agreement provides for a strategic focus in advancing I-Mab's potential ...

I-Mab Announces Participation at Jefferies and Piper Conferences in November PR Newswire ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differe...

2023-11-02 10:07:57 ET More on I-Mab, Morphic, etc. Morphic Holding: The Price Drop Is Very Interesting I-Mab: Why This Company Trades At A Third The Value Of Its Cash I-Mab (IMAB) Q2 2023 Earnings Call Transcript MorphoSys expects a 5% surge in Monjuvi sales...